The stock of Caredx Inc (CDNA) has seen a 0.37% increase in the past week, with a 16.74% gain in the past month, and a 6.75% flourish in the past quarter. The volatility ratio for the week is 3.69%, and the volatility levels for the past 30 days are at 4.04% for CDNA. The simple moving average for the last 20 days is 4.75% for CDNA’s stock, with a simple moving average of -15.84% for the last 200 days.
Is It Worth Investing in Caredx Inc (NASDAQ: CDNA) Right Now?
Caredx Inc (NASDAQ: CDNA) has a higher price-to-earnings ratio of 16.34x compared to its average ratio. CDNA has 36-month beta value of 2.19. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for CDNA is 52.00M, and currently, short sellers hold a 12.50% ratio of that float. The average trading volume of CDNA on June 13, 2025 was 1.02M shares.
CDNA) stock’s latest price update
Caredx Inc (NASDAQ: CDNA)’s stock price has dropped by -6.23 in relation to previous closing price of 20.08. Nevertheless, the company has seen a gain of 0.37% in its stock price over the last five trading days. businesswire.com reported 2025-06-03 that BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA), – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it has completed the repurchase of $50 million of its common stock representing approximately 5% of outstanding shares. The share repurchase follows the completion of the company’s seven.
Analysts’ Opinion of CDNA
Many brokerage firms have already submitted their reports for CDNA stocks, with Wells Fargo repeating the rating for CDNA by listing it as a “Equal Weight.” The predicted price for CDNA in the upcoming period, according to Wells Fargo is $24 based on the research report published on January 15, 2025 of the current year 2025.
Wells Fargo, on the other hand, stated in their research note that they expect to see CDNA reach a price target of $28. The rating they have provided for CDNA stocks is “Underweight” according to the report published on August 28th, 2024.
BTIG Research gave a rating of “Buy” to CDNA, setting the target price at $40 in the report published on August 19th of the previous year.
CDNA Trading at 7.77% from the 50-Day Moving Average
After a stumble in the market that brought CDNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.95% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CDNA starting from WILLIAM HAGSTROM, who proposed sale 19,391 shares at the price of $19.90 back on Jun 11 ’25. After this action, WILLIAM HAGSTROM now owns shares of Caredx Inc, valued at $385,918 using the latest closing price.
HAGSTROM WILLIAM A, the Director of Caredx Inc, sale 30,000 shares at $17.45 during a trade that took place back on May 28 ’25, which means that HAGSTROM WILLIAM A is holding 53,979 shares at $523,413 based on the most recent closing price.
Stock Fundamentals for CDNA
Current profitability levels for the company are sitting at:
- 0.14 for the present operating margin
- 0.67 for the gross margin
The net margin for Caredx Inc stands at 0.17. The total capital return value is set at 0.12. Equity return is now at value 21.57, with 14.55 for asset returns.
Based on Caredx Inc (CDNA), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at 0.88.
Currently, EBITDA for the company is -33.99 million with net debt to EBITDA at -0.88. When we switch over and look at the enterprise to sales, we see a ratio of 2.86. The receivables turnover for the company is 4.85for trailing twelve months and the total asset turnover is 0.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.11.
Conclusion
To put it simply, Caredx Inc (CDNA) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
